Clinical Trial Update: 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis. [Phase 2]

View source ↗

Summary

A Phase 2 trial using 31P-MRS imaging to evaluate CNM-Au8's effects on impaired neuronal redox state in people with Multiple Sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• CNM-Au8 (CNM-Au8)

Snippet

Sponsor: Clene Nanomedicine | Conditions: Multiple Sclerosis | Phase 2 | Status: COMPLETED